Promising Developments and Market Potential Drive Buy Rating for Urogen Pharma’s Zusduri

Analyst Tara Bancroft from TD Cowen reiterated a Buy rating on Urogen Pharma and keeping the price target at $35.00.

Tara Bancroft’s rating is based on several promising developments surrounding Urogen Pharma’s product, Zusduri. The launch of Zusduri in the treatment of recurrent LG/IR NMIBC has shown significant early progress, with the company successfully activating numerous sites and establishing necessary logistics, such as specialty distribution and patient enrollment approvals. This progress is indicative of the company’s ability to meet its initial targets and suggests a strong market presence.
Bancroft also highlights the potential market share for Zusduri, with expectations that it could capture a substantial portion of the market by 2026. The anticipated improvements in patient conversion rates and remittance times, along with the upcoming permanent J code, are expected to further accelerate Zusduri’s adoption. These factors contribute to a positive outlook for Urogen Pharma, supporting the Buy rating.

In another report released on September 17, H.C. Wainwright also maintained a Buy rating on the stock with a $40.00 price target.

Based on the recent corporate insider activity of 8 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of URGN in relation to earlier this year.